MS neurologist Pavle Repovic talks about TRANSFORMS trial in Neurology Today

September 18, 2015

A post-hoc analysis of follow-up data from the TRANSFORMS trial suggests that early disease activity during a patient’s first year on fingolimod predicts longer-term outcomes in multiple sclerosis. Click here to read the analysis by Pavle Repovic, a neurologist at the Swedish Multiple Sclerosis Center.